Weekly shot could replace daily HIV pills for some patients

NCT ID NCT02859961

Completed Disease control Sponsor: CytoDyn, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a weekly injection of PRO 140 (Leronlimab) could keep HIV under control in people whose virus was already suppressed by daily pills. Over 500 participants switched from their regular medication to the shot alone for 48 weeks. The goal was to see how many could maintain viral suppression without their virus rebounding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRO 140 (Leronlimab) injection
What this could lead to: If successful, this could offer a simpler, long-acting maintenance option for people with HIV, reducing the need for daily pills.
What could go wrong: This is an early-to-mid stage trial with a moderate number of participants. The treatment may not work for everyone, and some patients experienced virologic failure. Long-term safety and effectiveness are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

CD03 Investigational site

La Mesa, California, 91942, United States
CD03 Investigational site

Palm Springs, California, 92262, United States
CD03 Investigational site

San Francisco, California, 94115, United States
CD03 Investigational site

New Haven, Connecticut, 06510, United States
CD03 Investigational site

Norwalk, Connecticut, 06850, United States
CD03 Investigational site

Ft. Pierce, Florida, 34982, United States
CD03 Investigational site

Orlando, Florida, 32803, United States
CD03 Investigational site

West Palm Beach, Florida, 33401, United States
CD03 Investigational site

Wichita, Kansas, 67214, United States
CD03 Investigational site

Las Vegas, Nevada, 89109, United States
CD03 Investigational site

New York, New York, 10011, United States
CD03 Investigational site

Syracuse, New York, 13210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.